These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32113900)
21. Dysregulated MicroRNA Involvement in Multiple Sclerosis by Induction of T Helper 17 Cell Differentiation. Chen C; Zhou Y; Wang J; Yan Y; Peng L; Qiu W Front Immunol; 2018; 9():1256. PubMed ID: 29915595 [TBL] [Abstract][Full Text] [Related]
22. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503 [TBL] [Abstract][Full Text] [Related]
24. New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression. Pesce S; Squillario M; Greppi M; Loiacono F; Moretta L; Moretta A; Sivori S; Castagnola P; Barla A; Candiani S; Marcenaro E Front Immunol; 2018; 9():2360. PubMed ID: 30374356 [TBL] [Abstract][Full Text] [Related]
25. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis. Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393 [TBL] [Abstract][Full Text] [Related]
26. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. Laroni A; Armentani E; Kerlero de Rosbo N; Ivaldi F; Marcenaro E; Sivori S; Gandhi R; Weiner HL; Moretta A; Mancardi GL; Uccelli A J Autoimmun; 2016 Aug; 72():8-18. PubMed ID: 27157273 [TBL] [Abstract][Full Text] [Related]
27. Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Bianchini E; De Biasi S; Simone AM; Ferraro D; Sola P; Cossarizza A; Pinti M Immunol Lett; 2017 Mar; 183():1-7. PubMed ID: 28119072 [TBL] [Abstract][Full Text] [Related]
28. Daclizumab Therapy for Multiple Sclerosis. Bielekova B Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 29661806 [TBL] [Abstract][Full Text] [Related]
29. Control of NK Cell Activation by Immune Checkpoint Molecules. Beldi-Ferchiou A; Caillat-Zucman S Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29023417 [TBL] [Abstract][Full Text] [Related]
30. Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Barilà G; Teramo A; Calabretto G; Ercolin C; Boscaro E; Trimarco V; Carraro S; Leoncin M; Vicenzetto C; Cabrelle A; Facco M; Piazza F; Semenzato G; Zambello R Blood Cancer J; 2018 Jun; 8(6):51. PubMed ID: 29891951 [No Abstract] [Full Text] [Related]
31. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. Ferlazzo G; Thomas D; Lin SL; Goodman K; Morandi B; Muller WA; Moretta A; Münz C J Immunol; 2004 Feb; 172(3):1455-62. PubMed ID: 14734722 [TBL] [Abstract][Full Text] [Related]
33. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759 [TBL] [Abstract][Full Text] [Related]
34. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. Fehniger TA; Shah MH; Turner MJ; VanDeusen JB; Whitman SP; Cooper MA; Suzuki K; Wechser M; Goodsaid F; Caligiuri MA J Immunol; 1999 Apr; 162(8):4511-20. PubMed ID: 10201989 [TBL] [Abstract][Full Text] [Related]
35. Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells. Villalba M; Alexia C; Bellin-Robert A; Fayd'herbe de Maudave A; Gitenay D Front Immunol; 2019; 10():3026. PubMed ID: 31998309 [TBL] [Abstract][Full Text] [Related]
36. Human CD56bright NK Cells: An Update. Michel T; Poli A; Cuapio A; Briquemont B; Iserentant G; Ollert M; Zimmer J J Immunol; 2016 Apr; 196(7):2923-31. PubMed ID: 26994304 [TBL] [Abstract][Full Text] [Related]
37. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW J Neuroimmunol; 1998 Jun; 86(2):123-33. PubMed ID: 9663557 [TBL] [Abstract][Full Text] [Related]